List of investigational attention deficit hyperactivity disorder drugs explained

This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

This list was last comprehensively updated in September 2021. It is likely to become outdated with time.

Under development

Preregistration

Phase 3 clinical trials

Phase 2 clinical trials

Phase 1 clinical trials

Preclinical/research

No development reported

Research programmes

Not under development

Development discontinued

Research programmes

Formal development never or not yet started

Clinically used drugs

Approved drugs

Norepinephrine–dopamine releasing agents

Norepinephrine–dopamine reuptake inhibitors

Norepinephrine reuptake inhibitors

α2-Adrenergic receptor agonists

Off-label drugs

See also

Further reading

External links

Notes and References

  1. Ceresoli-Borroni G, Nasser A, Adewole T, Liranso T, Xu J, Schwabe S, Findling RL . A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD . J Atten Disord . 25 . 11 . 1564–1577 . September 2021 . 32338106 . 10.1177/1087054720909084 . 216556900 .
  2. Robb AS, Connor DF, Amann BH, Vitiello B, Nasser A, O'Neal W, Schwabe S, Ceresoli-Borroni G, Newcorn JH, Candler SA, Buitelaar JK, Findling RL . Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents . CNS Spectr . 26. 5. 448–456 . March 2020 . 32228725 . 10.1017/S1092852920001224 . 214750205 . 2066/241059 . free .
  3. Hjorth S, Waters S, Waters N, Tedroff J, Svensson P, Fagerberg A, Edling M, Svanberg B, Ljung E, Gunnergren J, McLean SL, Grayson B, Idris NF, Neill JC, Sonesson C . (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent . J Pharmacol Exp Ther . 374 . 3 . 404–419 . September 2020 . 32605972 . 10.1124/jpet.120.000037 . 10454/17970 . 220283184 . free .
  4. Wilens TE, Morrison NR, Prince J . An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults . Expert Rev Neurother . 11 . 10 . 1443–65 . October 2011 . 21955201. 3229037 . 10.1586/ern.11.137 .
  5. Heal DJ, Smith SL, Gosden J, Nutt DJ . Amphetamine, past and present--a pharmacological and clinical perspective . J Psychopharmacol . 27 . 6 . 479–96 . June 2013 . 23539642 . 3666194 . 10.1177/0269881113482532 .
  6. Buoli M, Serati M, Cahn W . Alternative pharmacological strategies for adult ADHD treatment: a systematic review . Expert Rev Neurother . 16 . 2 . 131–44 . 2016 . 26693882 . 10.1586/14737175.2016.1135735 . 33004517 .
  7. Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S, Nunes Filipe C, Stes S, Mohr P, Leppämäki S, Casas M, Bobes J, Mccarthy JM, Richarte V, Kjems Philipsen A, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, Motavalli Mukaddes N, Brudkiewicz P, Gustafsson P, Tani P, Oswald P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, Pallanti S, Young S, Bejerot S, Lehtonen T, Kustow J, Müller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Félegyházy Z, Garcia-Portilla MP, Asherson P . Updated European Consensus Statement on diagnosis and treatment of adult ADHD . Eur Psychiatry . 56 . 14–34 . February 2019 . 30453134 . 10.1016/j.eurpsy.2018.11.001 . free . 10651/51910 . free .